PriceTargets.com logo

Prestige Consumer Healthcare - PBH Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $77.40
  • Forecasted Upside: 24.80%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$62.02 As of 03/30/2023 01:00 AM ET
▲ +0.53 (0.86%)

This chart shows the closing price for PBH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Prestige Consumer Healthcare Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PBH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PBH

Analyst Price Target is $77.40
▲ +24.80% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Prestige Consumer Healthcare in the last 3 months. The average price target is $77.40, with a high forecast of $104.00 and a low forecast of $70.00. The average price target represents a 24.80% upside from the last price of $62.02.

This chart shows the closing price for PBH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 6 contributing investment analysts is to buy stock in Prestige Consumer Healthcare. This rating has held steady since May 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
4/4/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
7/3/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/1/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/30/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/28/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2023

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/17/2023Royal Bank of CanadaLower TargetSector Perform$107.00 ➝ $104.00Low
2/17/2023OppenheimerLower TargetOutperform$72.00 ➝ $71.00Low
1/13/2023OppenheimerBoost TargetOutperform$63.00 ➝ $72.00Low
11/17/2022Canaccord Genuity GroupInitiated CoverageBuy$71.00Low
11/16/2022Canaccord Genuity GroupInitiated CoverageBuy$71.00Low
9/29/2022OppenheimerLower Target$63.00Low
8/9/2022DA DavidsonReiterated RatingNeutralLow
5/10/2022Jefferies Financial GroupUpgradeHold ➝ Buy$65.00 ➝ $70.00High
5/9/2022OppenheimerUpgradeMarket Perform ➝ Outperform$63.00High
11/15/2021DA DavidsonBoost TargetNeutral$61.00 ➝ $63.00High
11/5/2021Royal Bank of CanadaBoost TargetSector Perform$123.00 ➝ $126.00High
8/6/2021Royal Bank of CanadaBoost TargetSector Perform$107.00 ➝ $123.00N/A
8/6/2021DA DavidsonBoost TargetNeutral$52.00 ➝ $61.00High
5/28/2021DA DavidsonBoost TargetNeutral$49.00 ➝ $52.00Medium
5/10/2021DA DavidsonBoost TargetNeutral$39.00 ➝ $49.00High
12/2/2020BMO Capital MarketsUpgradeOutperform$125.00Low
11/9/2020CIBCBoost TargetNeutral$100.00 ➝ $103.00Medium
11/6/2020TD SecuritiesBoost TargetBuy$115.00 ➝ $125.00High
11/6/2020BMO Capital MarketsBoost TargetMarket Perform$106.00 ➝ $112.00High
11/6/2020DA DavidsonLower TargetNeutral$45.00 ➝ $39.00High
8/7/2020DA DavidsonDowngradeBuy ➝ Neutral$49.00 ➝ $45.00High
7/24/2020BMO Capital MarketsBoost TargetMarket Perform$91.00 ➝ $95.00Low
7/24/2020TD SecuritiesBoost TargetHold$90.00 ➝ $97.00Low
6/29/2020SidotiUpgradeNeutral ➝ Buy$46.00High
6/17/2020OppenheimerReiterated RatingHoldLow
5/12/2020CIBCBoost TargetNeutral$86.00 ➝ $88.00High
5/12/2020BMO Capital MarketsBoost TargetMarket Perform$85.00 ➝ $91.00High
4/15/2020DA DavidsonBoost Target$43.00 ➝ $47.00Medium
4/14/2020TD SecuritiesDowngradeHold$86.00High
4/14/2020Jefferies Financial GroupDowngradeBuy ➝ HoldHigh
4/7/2020SidotiInitiated CoverageNeutralLow
3/26/2020Jefferies Financial GroupUpgradeHold ➝ Buy$43.00High
3/23/2020OppenheimerInitiated CoverageMarket PerformHigh
3/19/2020DA DavidsonUpgradeNeutral ➝ BuyHigh
2/7/2020DA DavidsonReiterated RatingNeutralHigh
1/30/2020BMO Capital MarketsBoost TargetOutperform$92.00 ➝ $106.00Low
5/27/2019CIBCReiterated RatingHold$84.00Medium
3/15/2019Royal Bank of CanadaReiterated RatingBuy$97.00Low
2/13/2019DesjardinsDowngradeHold$88.00Low
1/15/2019Raymond JamesDowngradeOutperform ➝ Market Perform$28.40Medium
11/5/2018DA DavidsonBoost TargetNeutral$38.00Low
8/2/2018Jefferies Financial GroupSet TargetHold$38.00High
5/8/2018DA DavidsonDowngradeNeutral$33.00Medium
(Data available from 3/30/2018 forward)

News Sentiment Rating

1.00 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/1/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/1/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/31/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
11/30/2022
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/30/2022
  • 8 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/29/2023
  • 9 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/28/2023
  • 13 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/30/2023

Current Sentiment

  • 13 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Prestige Consumer Healthcare logo
Prestige Consumer Healthcare, Inc. engages in the marketing, sale, and distribution of pharmaceutical drugs and consumer products. It operates through the following segments: North American OTC Healthcare and International OTC Healthcare. The North American and International OTC Healthcare segments manages the following brands: BC/Goody's, Beano, Boudreaux's Butt Paste, Chloraseptic, Clear Eyes, Compound W, Debrox, DenTek, Dramamine, Efferdent, Fess, Fleet, Gaviscon, Hydralyte, Luden's, Monistat, Nix, Pedia-Lax, and Summer's Eve. The company was founded in 1996 and is headquartered in Tarrytown, NY.
Read More

Today's Range

Now: $62.02
Low: $61.28
High: $62.09

50 Day Range

MA: $61.65
Low: $58.41
High: $67.05

52 Week Range

Now: $62.02
Low: $48.51
High: $67.45

Volume

164,366 shs

Average Volume

284,696 shs

Market Capitalization

$3.08 billion

P/E Ratio

14.87

Dividend Yield

N/A

Beta

0.56

Frequently Asked Questions

What sell-side analysts currently cover shares of Prestige Consumer Healthcare?

The following Wall Street sell-side analysts have issued research reports on Prestige Consumer Healthcare in the last twelve months: Canaccord Genuity Group Inc., DA Davidson, Jefferies Financial Group Inc., Oppenheimer Holdings Inc., Royal Bank of Canada, and StockNews.com.
View the latest analyst ratings for PBH.

What is the current price target for Prestige Consumer Healthcare?

5 Wall Street analysts have set twelve-month price targets for Prestige Consumer Healthcare in the last year. Their average twelve-month price target is $77.40, suggesting a possible upside of 24.8%. Royal Bank of Canada has the highest price target set, predicting PBH will reach $104.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $70.00 for Prestige Consumer Healthcare in the next year.
View the latest price targets for PBH.

What is the current consensus analyst rating for Prestige Consumer Healthcare?

Prestige Consumer Healthcare currently has 2 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PBH will outperform the market and that investors should add to their positions of Prestige Consumer Healthcare.
View the latest ratings for PBH.

What other companies compete with Prestige Consumer Healthcare?

Other companies that are similar to Prestige Consumer Healthcare include PowerSchool, Travel + Leisure, Grupo Televisa, S.A.B., Acushnet and Graham. Learn More about companies similar to Prestige Consumer Healthcare.

How do I contact Prestige Consumer Healthcare's investor relations team?

Prestige Consumer Healthcare's physical mailing address is 660 WHITE PLAINS ROAD SUITE 250, TARRYTOWN NY, 10591. The company's listed phone number is (914) 524-6800 and its investor relations email address is [email protected] The official website for Prestige Consumer Healthcare is www.prestigebrands.com. Learn More about contacing Prestige Consumer Healthcare investor relations.